Interference of tumor necrosis factor inhibitor treatments on soluble tumor necrosis factor receptor 2 levels in rheumatoid arthritis
Identifieur interne : 000663 ( Pmc/Checkpoint ); précédent : 000662; suivant : 000664Interference of tumor necrosis factor inhibitor treatments on soluble tumor necrosis factor receptor 2 levels in rheumatoid arthritis
Auteurs : Nicole Yang [États-Unis] ; Jie Huang [États-Unis] ; Michelle Frits [États-Unis] ; Christine Iannaccone [États-Unis] ; Michael E. Weinblatt [États-Unis] ; Nader Rifai [États-Unis] ; Nancy Shadick [États-Unis] ; Gary Bradwin [États-Unis] ; Katherine P. Liao [États-Unis]Source :
- Practical Laboratory Medicine [ 2352-5517 ] ; 2019.
Abstract
Soluble Tumor Necrosis Factor Receptor II (sTNFR2) is used as a biomarker to study cardiovascular disease (CVD) in diverse populations. TNF inhibitors (TNFi's) are a common treatment for inflammatory conditions. The objective of this study was to examine whether TNFi use impacts measured sTNFR2 levels.
We studied blood samples from a cohort of RA patients with clinical data and high sensitivity-C-reactive protein (hsCRP) measurements. To assess for interference, we tested the entire cohort for the expected positive correlation between sTNFR2 and TNFi using Pearson correlations. We then performed Pearson correlations between sTNFR2 and TNFi and sequentially removed subjects on adalimumab, etanercept, and infliximab; if interference was occurring, no correlation would be observed between hsCRP and sTNFR2, and correlation would be restored by removing subjects on the treatment causing the interference.
We studied 190 subjects, 84.2% female, 73.4% anti-CCP positive. All subjects with sTNFR2 level exceeding measurable level were on etanercept. The expected positive correlation between hsCRP and sTNFR2 was not observed when assessing the entire cohort, r = 0.05, p = 0.51. However, the expected correlation was restored only after excluding subjects on etanercept, r = 0.46, p < 0.0001, and not adalimumab or infliximab. ELISA for sTNFR2 was performed using etanercept only and demonstrated direct binding to sTNFR2.
Our data identified interference between etanercept and the TNFR2 assay. Of the TNFi's, only etanercept has a TNF-binding domain modeled after TNFR2. These data should be considered when designing studies using sTNFR2 in populations where etanercept is a treatment option.
Url:
DOI: 10.1016/j.plabm.2019.e00122
PubMed: 31193412
PubMed Central: 6527918
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
PMC:6527918Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Interference of tumor necrosis factor inhibitor treatments on soluble tumor necrosis factor receptor 2 levels in rheumatoid arthritis</title><author><name sortKey="Yang, Nicole" sort="Yang, Nicole" uniqKey="Yang N" first="Nicole" last="Yang">Nicole Yang</name><affiliation wicri:level="1"><nlm:aff id="aff2">Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA</wicri:regionArea><wicri:noRegion>MA</wicri:noRegion></affiliation></author><author><name sortKey="Huang, Jie" sort="Huang, Jie" uniqKey="Huang J" first="Jie" last="Huang">Jie Huang</name><affiliation wicri:level="1"><nlm:aff id="aff2">Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA</wicri:regionArea><wicri:noRegion>MA</wicri:noRegion></affiliation></author><author><name sortKey="Frits, Michelle" sort="Frits, Michelle" uniqKey="Frits M" first="Michelle" last="Frits">Michelle Frits</name><affiliation wicri:level="1"><nlm:aff id="aff2">Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA</wicri:regionArea><wicri:noRegion>MA</wicri:noRegion></affiliation></author><author><name sortKey="Iannaccone, Christine" sort="Iannaccone, Christine" uniqKey="Iannaccone C" first="Christine" last="Iannaccone">Christine Iannaccone</name><affiliation wicri:level="1"><nlm:aff id="aff2">Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA</wicri:regionArea><wicri:noRegion>MA</wicri:noRegion></affiliation></author><author><name sortKey="Weinblatt, Michael E" sort="Weinblatt, Michael E" uniqKey="Weinblatt M" first="Michael E." last="Weinblatt">Michael E. Weinblatt</name><affiliation wicri:level="1"><nlm:aff id="aff2">Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA</wicri:regionArea><wicri:noRegion>MA</wicri:noRegion></affiliation></author><author><name sortKey="Rifai, Nader" sort="Rifai, Nader" uniqKey="Rifai N" first="Nader" last="Rifai">Nader Rifai</name><affiliation wicri:level="1"><nlm:aff id="aff3">Department of Laboratory Medicine, Boston Children's Hospital, Boston, MA, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Laboratory Medicine, Boston Children's Hospital, Boston, MA</wicri:regionArea><wicri:noRegion>MA</wicri:noRegion></affiliation></author><author><name sortKey="Shadick, Nancy" sort="Shadick, Nancy" uniqKey="Shadick N" first="Nancy" last="Shadick">Nancy Shadick</name><affiliation wicri:level="1"><nlm:aff id="aff2">Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA</wicri:regionArea><wicri:noRegion>MA</wicri:noRegion></affiliation></author><author><name sortKey="Bradwin, Gary" sort="Bradwin, Gary" uniqKey="Bradwin G" first="Gary" last="Bradwin">Gary Bradwin</name><affiliation wicri:level="1"><nlm:aff id="aff3">Department of Laboratory Medicine, Boston Children's Hospital, Boston, MA, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Laboratory Medicine, Boston Children's Hospital, Boston, MA</wicri:regionArea><wicri:noRegion>MA</wicri:noRegion></affiliation></author><author><name sortKey="Liao, Katherine P" sort="Liao, Katherine P" uniqKey="Liao K" first="Katherine P." last="Liao">Katherine P. Liao</name><affiliation wicri:level="1"><nlm:aff id="aff2">Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA</wicri:regionArea><wicri:noRegion>MA</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">31193412</idno><idno type="pmc">6527918</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6527918</idno><idno type="RBID">PMC:6527918</idno><idno type="doi">10.1016/j.plabm.2019.e00122</idno><date when="2019">2019</date><idno type="wicri:Area/Pmc/Corpus">000267</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000267</idno><idno type="wicri:Area/Pmc/Curation">000267</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000267</idno><idno type="wicri:Area/Pmc/Checkpoint">000663</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000663</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Interference of tumor necrosis factor inhibitor treatments on soluble tumor necrosis factor receptor 2 levels in rheumatoid arthritis</title><author><name sortKey="Yang, Nicole" sort="Yang, Nicole" uniqKey="Yang N" first="Nicole" last="Yang">Nicole Yang</name><affiliation wicri:level="1"><nlm:aff id="aff2">Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA</wicri:regionArea><wicri:noRegion>MA</wicri:noRegion></affiliation></author><author><name sortKey="Huang, Jie" sort="Huang, Jie" uniqKey="Huang J" first="Jie" last="Huang">Jie Huang</name><affiliation wicri:level="1"><nlm:aff id="aff2">Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA</wicri:regionArea><wicri:noRegion>MA</wicri:noRegion></affiliation></author><author><name sortKey="Frits, Michelle" sort="Frits, Michelle" uniqKey="Frits M" first="Michelle" last="Frits">Michelle Frits</name><affiliation wicri:level="1"><nlm:aff id="aff2">Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA</wicri:regionArea><wicri:noRegion>MA</wicri:noRegion></affiliation></author><author><name sortKey="Iannaccone, Christine" sort="Iannaccone, Christine" uniqKey="Iannaccone C" first="Christine" last="Iannaccone">Christine Iannaccone</name><affiliation wicri:level="1"><nlm:aff id="aff2">Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA</wicri:regionArea><wicri:noRegion>MA</wicri:noRegion></affiliation></author><author><name sortKey="Weinblatt, Michael E" sort="Weinblatt, Michael E" uniqKey="Weinblatt M" first="Michael E." last="Weinblatt">Michael E. Weinblatt</name><affiliation wicri:level="1"><nlm:aff id="aff2">Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA</wicri:regionArea><wicri:noRegion>MA</wicri:noRegion></affiliation></author><author><name sortKey="Rifai, Nader" sort="Rifai, Nader" uniqKey="Rifai N" first="Nader" last="Rifai">Nader Rifai</name><affiliation wicri:level="1"><nlm:aff id="aff3">Department of Laboratory Medicine, Boston Children's Hospital, Boston, MA, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Laboratory Medicine, Boston Children's Hospital, Boston, MA</wicri:regionArea><wicri:noRegion>MA</wicri:noRegion></affiliation></author><author><name sortKey="Shadick, Nancy" sort="Shadick, Nancy" uniqKey="Shadick N" first="Nancy" last="Shadick">Nancy Shadick</name><affiliation wicri:level="1"><nlm:aff id="aff2">Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA</wicri:regionArea><wicri:noRegion>MA</wicri:noRegion></affiliation></author><author><name sortKey="Bradwin, Gary" sort="Bradwin, Gary" uniqKey="Bradwin G" first="Gary" last="Bradwin">Gary Bradwin</name><affiliation wicri:level="1"><nlm:aff id="aff3">Department of Laboratory Medicine, Boston Children's Hospital, Boston, MA, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Laboratory Medicine, Boston Children's Hospital, Boston, MA</wicri:regionArea><wicri:noRegion>MA</wicri:noRegion></affiliation></author><author><name sortKey="Liao, Katherine P" sort="Liao, Katherine P" uniqKey="Liao K" first="Katherine P." last="Liao">Katherine P. Liao</name><affiliation wicri:level="1"><nlm:aff id="aff2">Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA, USA</nlm:aff><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA</wicri:regionArea><wicri:noRegion>MA</wicri:noRegion></affiliation></author></analytic><series><title level="j">Practical Laboratory Medicine</title><idno type="eISSN">2352-5517</idno><imprint><date when="2019">2019</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec><title>Objective</title><p>Soluble Tumor Necrosis Factor Receptor II (sTNFR2) is used as a biomarker to study cardiovascular disease (CVD) in diverse populations. TNF inhibitors (TNFi's) are a common treatment for inflammatory conditions. The objective of this study was to examine whether TNFi use impacts measured sTNFR2 levels.</p></sec><sec><title>Methods</title><p>We studied blood samples from a cohort of RA patients with clinical data and high sensitivity-C-reactive protein (hsCRP) measurements. To assess for interference, we tested the entire cohort for the expected positive correlation between sTNFR2 and TNFi using Pearson correlations. We then performed Pearson correlations between sTNFR2 and TNFi and sequentially removed subjects on adalimumab, etanercept, and infliximab; if interference was occurring, no correlation would be observed between hsCRP and sTNFR2, and correlation would be restored by removing subjects on the treatment causing the interference.</p></sec><sec><title>Results</title><p>We studied 190 subjects, 84.2% female, 73.4% anti-CCP positive. All subjects with sTNFR2 level exceeding measurable level were on etanercept. The expected positive correlation between hsCRP and sTNFR2 was not observed when assessing the entire cohort, r = 0.05, p = 0.51. However, the expected correlation was restored only after excluding subjects on etanercept, r = 0.46, p < 0.0001, and not adalimumab or infliximab. ELISA for sTNFR2 was performed using etanercept only and demonstrated direct binding to sTNFR2.</p></sec><sec><title>Conclusions</title><p>Our data identified interference between etanercept and the TNFR2 assay. Of the TNFi's, only etanercept has a TNF-binding domain modeled after TNFR2. These data should be considered when designing studies using sTNFR2 in populations where etanercept is a treatment option.</p></sec></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Vasan, R S" uniqKey="Vasan R">R.S. Vasan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bluml, S" uniqKey="Bluml S">S. Bluml</name></author><author><name sortKey="Scheinecker, C" uniqKey="Scheinecker C">C. Scheinecker</name></author><author><name sortKey="Smolen, J S" uniqKey="Smolen J">J.S. Smolen</name></author><author><name sortKey="Redlich, K" uniqKey="Redlich K">K. Redlich</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Karlson, E W" uniqKey="Karlson E">E.W. Karlson</name></author><author><name sortKey="Chibnik, L B" uniqKey="Chibnik L">L.B. Chibnik</name></author><author><name sortKey="Tworoger, S S" uniqKey="Tworoger S">S.S. Tworoger</name></author><author><name sortKey="Lee, I M" uniqKey="Lee I">I.M. Lee</name></author><author><name sortKey="Buring, J E" uniqKey="Buring J">J.E. Buring</name></author><author><name sortKey="Shadick, N A" uniqKey="Shadick N">N.A. Shadick</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chakrabarti, S" uniqKey="Chakrabarti S">S. Chakrabarti</name></author><author><name sortKey="Davidge, S T" uniqKey="Davidge S">S.T. Davidge</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Doss, G P" uniqKey="Doss G">G.P. Doss</name></author><author><name sortKey="Agoramoorthy, G" uniqKey="Agoramoorthy G">G. Agoramoorthy</name></author><author><name sortKey="Chakraborty, C" uniqKey="Chakraborty C">C. Chakraborty</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Welsh, P" uniqKey="Welsh P">P. Welsh</name></author><author><name sortKey="Grassia, G" uniqKey="Grassia G">G. Grassia</name></author><author><name sortKey="Bota, S" uniqKey="Bota S">S. Bota</name></author><author><name sortKey="Sattar, N" uniqKey="Sattar N">N. Sattar</name></author><author><name sortKey="Maffia, P" uniqKey="Maffia P">P. Maffia</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Rho, Y H" uniqKey="Rho Y">Y.H. Rho</name></author><author><name sortKey="Chung, C P" uniqKey="Chung C">C.P. Chung</name></author><author><name sortKey="Oeser, A" uniqKey="Oeser A">A. Oeser</name></author><author><name sortKey="Solus, J" uniqKey="Solus J">J. Solus</name></author><author><name sortKey="Asanuma, Y" uniqKey="Asanuma Y">Y. Asanuma</name></author><author><name sortKey="Sokka, T" uniqKey="Sokka T">T. Sokka</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dibbs, Z" uniqKey="Dibbs Z">Z. Dibbs</name></author><author><name sortKey="Thornby, J" uniqKey="Thornby J">J. Thornby</name></author><author><name sortKey="White, B G" uniqKey="White B">B.G. White</name></author><author><name sortKey="Mann, D L" uniqKey="Mann D">D.L. Mann</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cope, A P" uniqKey="Cope A">A.P. Cope</name></author><author><name sortKey="Aderka, D" uniqKey="Aderka D">D. Aderka</name></author><author><name sortKey="Doherty, M" uniqKey="Doherty M">M. Doherty</name></author><author><name sortKey="Engelmann, H" uniqKey="Engelmann H">H. Engelmann</name></author><author><name sortKey="Gibbons, D" uniqKey="Gibbons D">D. Gibbons</name></author><author><name sortKey="Jones, A C" uniqKey="Jones A">A.C. Jones</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Steiner, G" uniqKey="Steiner G">G. Steiner</name></author><author><name sortKey="Studnicka Benke, A" uniqKey="Studnicka Benke A">A. Studnicka-Benke</name></author><author><name sortKey="Witzmann, G" uniqKey="Witzmann G">G. Witzmann</name></author><author><name sortKey="Hofler, E" uniqKey="Hofler E">E. Hofler</name></author><author><name sortKey="Smolen, J" uniqKey="Smolen J">J. Smolen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Iannaccone, C K" uniqKey="Iannaccone C">C.K. Iannaccone</name></author><author><name sortKey="Lee, Y C" uniqKey="Lee Y">Y.C. Lee</name></author><author><name sortKey="Cui, J" uniqKey="Cui J">J. Cui</name></author><author><name sortKey="Frits, M L" uniqKey="Frits M">M.L. Frits</name></author><author><name sortKey="Glass, R J" uniqKey="Glass R">R.J. Glass</name></author><author><name sortKey="Plenge, R M" uniqKey="Plenge R">R.M. Plenge</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Aziz, N" uniqKey="Aziz N">N. Aziz</name></author><author><name sortKey="Fahey, J L" uniqKey="Fahey J">J.L. Fahey</name></author><author><name sortKey="Detels, R" uniqKey="Detels R">R. Detels</name></author><author><name sortKey="Butch, A W" uniqKey="Butch A">A.W. Butch</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zakynthinos, E" uniqKey="Zakynthinos E">E. Zakynthinos</name></author><author><name sortKey="Pappa, N" uniqKey="Pappa N">N. Pappa</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="brief-report"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Pract Lab Med</journal-id><journal-id journal-id-type="iso-abbrev">Pract Lab Med</journal-id><journal-title-group><journal-title>Practical Laboratory Medicine</journal-title></journal-title-group><issn pub-type="epub">2352-5517</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31193412</article-id><article-id pub-id-type="pmc">6527918</article-id><article-id pub-id-type="publisher-id">S2352-5517(18)30029-5</article-id><article-id pub-id-type="doi">10.1016/j.plabm.2019.e00122</article-id><article-id pub-id-type="publisher-id">e00122</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Interference of tumor necrosis factor inhibitor treatments on soluble tumor necrosis factor receptor 2 levels in rheumatoid arthritis</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Nicole</given-names></name><xref rid="aff2" ref-type="aff">a</xref><xref rid="aff1" ref-type="fn">1</xref></contrib><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Jie</given-names></name><xref rid="aff2" ref-type="aff">a</xref><xref rid="aff1" ref-type="fn">1</xref></contrib><contrib contrib-type="author"><name><surname>Frits</surname><given-names>Michelle</given-names></name><xref rid="aff2" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Iannaccone</surname><given-names>Christine</given-names></name><xref rid="aff2" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Weinblatt</surname><given-names>Michael E.</given-names></name><xref rid="aff2" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Rifai</surname><given-names>Nader</given-names></name><xref rid="aff3" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Shadick</surname><given-names>Nancy</given-names></name><xref rid="aff2" ref-type="aff">a</xref></contrib><contrib contrib-type="author"><name><surname>Bradwin</surname><given-names>Gary</given-names></name><xref rid="aff3" ref-type="aff">b</xref></contrib><contrib contrib-type="author"><name><surname>Liao</surname><given-names>Katherine P.</given-names></name><email>kliao@bwh.harvard.edu</email><xref rid="aff2" ref-type="aff">a</xref><xref rid="cor1" ref-type="corresp">∗</xref></contrib></contrib-group><aff id="aff2"><label>a</label>Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Boston, MA, USA</aff><aff id="aff3"><label>b</label>Department of Laboratory Medicine, Boston Children's Hospital, Boston, MA, USA</aff><author-notes><corresp id="cor1"><label>∗</label>Corresponding author. Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, 60 Fenwood Road, Boston, MA, 02115, USA. <email>kliao@bwh.harvard.edu</email></corresp><fn id="aff1"><label>1</label><p id="ntpara0010">Authors contributed equally to the study.</p></fn></author-notes><pub-date pub-type="pmc-release"><day>03</day><month>5</month><year>2019</year></pub-date><pmc-comment> PMC Release delay is 0 months and 0 days and was based on .</pmc-comment>
<pub-date pub-type="collection"><month>8</month><year>2019</year></pub-date><pub-date pub-type="epub"><day>03</day><month>5</month><year>2019</year></pub-date><volume>16</volume><elocation-id>e00122</elocation-id><history><date date-type="received"><day>3</day><month>3</month><year>2018</year></date><date date-type="rev-recd"><day>25</day><month>3</month><year>2019</year></date><date date-type="accepted"><day>17</day><month>4</month><year>2019</year></date></history><permissions><copyright-statement>© 2019 The Authors</copyright-statement><copyright-year>2019</copyright-year><license license-type="CC BY-NC-ND" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/"><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><abstract id="abs0010"><sec><title>Objective</title><p>Soluble Tumor Necrosis Factor Receptor II (sTNFR2) is used as a biomarker to study cardiovascular disease (CVD) in diverse populations. TNF inhibitors (TNFi's) are a common treatment for inflammatory conditions. The objective of this study was to examine whether TNFi use impacts measured sTNFR2 levels.</p></sec><sec><title>Methods</title><p>We studied blood samples from a cohort of RA patients with clinical data and high sensitivity-C-reactive protein (hsCRP) measurements. To assess for interference, we tested the entire cohort for the expected positive correlation between sTNFR2 and TNFi using Pearson correlations. We then performed Pearson correlations between sTNFR2 and TNFi and sequentially removed subjects on adalimumab, etanercept, and infliximab; if interference was occurring, no correlation would be observed between hsCRP and sTNFR2, and correlation would be restored by removing subjects on the treatment causing the interference.</p></sec><sec><title>Results</title><p>We studied 190 subjects, 84.2% female, 73.4% anti-CCP positive. All subjects with sTNFR2 level exceeding measurable level were on etanercept. The expected positive correlation between hsCRP and sTNFR2 was not observed when assessing the entire cohort, r = 0.05, p = 0.51. However, the expected correlation was restored only after excluding subjects on etanercept, r = 0.46, p < 0.0001, and not adalimumab or infliximab. ELISA for sTNFR2 was performed using etanercept only and demonstrated direct binding to sTNFR2.</p></sec><sec><title>Conclusions</title><p>Our data identified interference between etanercept and the TNFR2 assay. Of the TNFi's, only etanercept has a TNF-binding domain modeled after TNFR2. These data should be considered when designing studies using sTNFR2 in populations where etanercept is a treatment option.</p></sec></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>Rheumatoid arthritis</kwd><kwd>Cardiovascular</kwd><kwd>Inflammation</kwd><kwd>Tumor necrosis factor inhibitor (TNFi)</kwd><kwd>High sensitivity C-reactive protein (hsCRP)</kwd><kwd>Biomarker</kwd></kwd-group></article-meta></front></pmc><affiliations><list><country><li>États-Unis</li></country></list><tree><country name="États-Unis"><noRegion><name sortKey="Yang, Nicole" sort="Yang, Nicole" uniqKey="Yang N" first="Nicole" last="Yang">Nicole Yang</name></noRegion><name sortKey="Bradwin, Gary" sort="Bradwin, Gary" uniqKey="Bradwin G" first="Gary" last="Bradwin">Gary Bradwin</name><name sortKey="Frits, Michelle" sort="Frits, Michelle" uniqKey="Frits M" first="Michelle" last="Frits">Michelle Frits</name><name sortKey="Huang, Jie" sort="Huang, Jie" uniqKey="Huang J" first="Jie" last="Huang">Jie Huang</name><name sortKey="Iannaccone, Christine" sort="Iannaccone, Christine" uniqKey="Iannaccone C" first="Christine" last="Iannaccone">Christine Iannaccone</name><name sortKey="Liao, Katherine P" sort="Liao, Katherine P" uniqKey="Liao K" first="Katherine P." last="Liao">Katherine P. Liao</name><name sortKey="Rifai, Nader" sort="Rifai, Nader" uniqKey="Rifai N" first="Nader" last="Rifai">Nader Rifai</name><name sortKey="Shadick, Nancy" sort="Shadick, Nancy" uniqKey="Shadick N" first="Nancy" last="Shadick">Nancy Shadick</name><name sortKey="Weinblatt, Michael E" sort="Weinblatt, Michael E" uniqKey="Weinblatt M" first="Michael E." last="Weinblatt">Michael E. Weinblatt</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Pmc/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000663 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd -nk 000663 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Pmc
|étape= Checkpoint
|type= RBID
|clé= PMC:6527918
|texte= Interference of tumor necrosis factor inhibitor treatments on soluble tumor necrosis factor receptor 2 levels in rheumatoid arthritis
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/RBID.i -Sk "pubmed:31193412" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a ChloroquineV1
| This area was generated with Dilib version V0.6.33. |  |